Bassi M, Nakamura N B, Furuya W I, Colombari D S A, Menani J V, do Carmo J M, da Silva A A, Hall J E, Colombari E
Department of Physiology and Pathology, School of Dentistry, São Paulo State University (UNESP), Araraquara, Brazil.
Acta Physiol (Oxf). 2015 Apr;213(4):893-901. doi: 10.1111/apha.12394. Epub 2014 Sep 30.
Melanocortin receptors (MC3/4R) mediate most of the metabolic and cardiovascular actions of leptin.
Here, we tested if MC4R also contributes to leptin's effects on respiratory function.
After control measurements, male Holtzman rats received daily microinjections of leptin, SHU9119 (MC3/4R antagonist) or SHU9119 combined with leptin infused into the brain lateral ventricle for 7 days. On the 6th day of treatment, tidal volume (VT ), respiratory frequency (fR ) and pulmonary ventilation (VE ) were measured by whole-body plethysmography during normocapnia or hypercapnia (7% CO2 ). Baseline mean arterial pressure (MAP), heart rate (HR) and metabolic rate were also measured. VE , VT and fR were also measured in mice with leptin receptor deletion in the entire central nervous system (LepR/Nestin-cre) or only in proopiomelanocortin neurones (LepR/POMC-cre) and in MC4R knockout (MC4R(-/-) ) and wild-type mice.
Leptin (5 μg day(-1) ) reduced body weight (17%) and increased ventilatory response to hypercapnia, whereas SHU9119 (0.6 nmol day(-1) ) increased body weight (18%) and reduced ventilatory responses compared with control-PBS group (Lep: 2119 ± 90 mL min(-1) kg(-1) and SHU9119: 997 ± 67 mL min(-1) kg(-1) , vs. PBS: 1379 ± 91 mL min(-1) kg(-1) ). MAP increased after leptin treatment (130 ± 2 mmHg) compared to PBS (106 ± 3 mmHg) or SHU9119 alone (109 ± 3 mmHg). SHU9119 prevented the effects of leptin on body weight, MAP (102 ± 3 mmHg) and ventilatory response to hypercapnia (1391 ± 137 mL min(-1) kg(-1) ). The ventilatory response to hypercapnia was attenuated in the LepR/Nestin-cre, LepR/POMC-cre and MC4R(-/-) mice.
These results suggest that central MC4R mediate the effects of leptin on respiratory response to hypercapnia.
黑皮质素受体(MC3/4R)介导了瘦素的大部分代谢和心血管作用。
在此,我们测试了MC4R是否也参与瘦素对呼吸功能的影响。
在进行对照测量后,雄性霍尔兹曼大鼠每天接受微量注射瘦素、SHU9119(MC3/4R拮抗剂)或SHU9119与瘦素联合注入脑侧脑室,持续7天。在治疗的第6天,通过全身体积描记法在正常碳酸血症或高碳酸血症(7%二氧化碳)期间测量潮气量(VT)、呼吸频率(fR)和肺通气量(VE)。还测量了基线平均动脉压(MAP)、心率(HR)和代谢率。在整个中枢神经系统中缺乏瘦素受体的小鼠(LepR/Nestin-cre)或仅在促肾上腺皮质激素原神经元中缺乏瘦素受体的小鼠(LepR/POMC-cre)以及MC4R基因敲除小鼠(MC4R(-/-))和野生型小鼠中也测量了VE、VT和fR。
瘦素(5μg·天(-1))使体重减轻(约17%),并增加了对高碳酸血症的通气反应,而SHU9119(0.6nmol·天(-1))使体重增加(约18%),与对照PBS组相比,通气反应降低(瘦素组:2119±90mL·min(-1)·kg(-1),SHU9119组:997±67mL·min(-1)·kg(-1),PBS组:1379±91mL·min(-1)·kg(-1))。与PBS(106±3mmHg)或单独的SHU9119(109±3mmHg)相比,瘦素治疗后MAP升高(130±2mmHg)。SHU9119可防止瘦素对体重、MAP(102±3mmHg)和对高碳酸血症的通气反应(1391±137mL·min(-1)·kg(-1))的影响。在LepR/Nestin-cre、LepR/POMC-cre和MC4R(-/-)小鼠中,对高碳酸血症的通气反应减弱。
这些结果表明,中枢MC4R介导了瘦素对高碳酸血症呼吸反应的影响。